openPR Logo
Press release

Transthyretin Amyloidosis Treatment Market is Expected To Witness A Robust CAGR of 55.4% Over The Forecast Period 2018–2026 Analysed With Global Players Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc.

03-11-2019 07:17 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Transthyretin Amyloidosis Treatment Market

Global Transthyretin Amyloidosis Treatment Market

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type. Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Request For In-Depth Sample Copy of Exclusive Report @ https://www.coherentmarketinsights.com/insight/request-sample/687

Transthyretin Amyloidosis Treatment Market - Key Players

Key players operating in the global transthyretin amyloidosis treatment market include,

1. Alnylam Pharmaceuticals, Inc.
2. Pfizer, Inc.
3. Prothena Corporation Plc.
4. GlaxoSmithKline Plc.
5. Ionis Pharmaceuticals, Inc.
6. Eidos Therapeutics
7. SOM Innovation Biotech, S.L.

Market Dynamics

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR. In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Introduction of novel therapy for the treatment of transthyretin amyloidosis is expected to significantly drive the market growth

Key players in the market are focused on approval and launch of novel therapies for treatment of transthyretin amyloidosis. This in turn is expected to propel growth of the global transthyretin amyloidosis treatment market over the forecast period. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Detailed Segmentation:

Global Transthyretin Amyloidosis Treatment Market, by Drug Type:
• Tafamidis (Vyndaqel)
• Patisiran (ONPATTRO)
• Inotersen (TEGSEDI)
• Others

Global Transthyretin Amyloidosis Treatment Market, by Disease Type:
• Hereditary Transthyretin Amyloidosis
• Polyneuropathy
• Cardiomyopathy
• Mixed Type
• Wild Type Amyloidosis

Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel:
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Transthyretin Amyloidosis Treatment Market, By Geography:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Else Place and Enquiry Before Purchase This Business Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/687

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Transthyretin Amyloidosis Treatment Market is Expected To Witness A Robust CAGR of 55.4% Over The Forecast Period 2018–2026 Analysed With Global Players Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc. here

News-ID: 1644392 • Views:

More Releases from Coherent Market Insights

Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clasado Biosciences, VW-Ingredients, Shandong Longli Biotechnology Co., Ltd, Prenexus Health., Ingredion, Tata Chemicals Ltd., Yakult Honsha Co., Ltd., Tate & Lyle, Roquette Frèr
Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clas …
Coherent Market Insights Published Most recent Prebiotics for Dietary Supplements Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business,
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., K
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca P …
Coherent Market Insights Published Most recent DNA Repair Drugs Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business, this
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, Manufacturing Process, Business Plan | Alpek S.A.B de C.V., RTP Company, BASF SE
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, M …
This comprehensive Report of the Polyethylene Terephthalate (PET) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requirement | BASF SE, Occidental Chemical Corporation
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requi …
This comprehensive Report of the Chlorine Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the market size

All 5 Releases


More Releases for Transthyretin

Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals
Transthyretin Amyloidosis Treatment Market Exhibit Skyrocketing Expansion During …
Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart. Transthyretin amyloidosis is a result of transthyretin produced by the liver and forms dimers, followed by monomers. Monomers aggregate to form amyloid fibrils, which are deposited in organs such as heart, nervous system,
Anti-Transthyretin Global Market Research Report 2025
Anti-Transthyretin Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/anti-transthyretin-market/80994 The report firstly introduced the Anti-Transthyretin basics: definitions, classifications, applications and market overview;
Transthyretin Global Market Research Report 2025
Transthyretin Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/transthyretin-market/80993 The report firstly introduced the Transthyretin basics: definitions, classifications, applications and market overview;
Global Transthyretin Amyloidosis (ATTR) Market 2018 Analysis By Size, Share | Tr …
Market Scenario The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period. Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia,
Transthyretin Amyloidosis Treatment Market - Global Industry Analysis 2025
Transthyretin amyloidosis is a rare disease caused due to abnormal build-up of amyloidosis in the tissues of the body. The deposits of transthyretin amyloids cause illness due to damage in structure and function of the organs and moreover, they can affect any part of the body where deposits of transthyretin amyloids are present. The deposits mainly consists of abnormal, insoluble protein fibers called amyloid fibrils that are soluble in healthy